Abstract 3861
Background
Eribulin is a novel microtubule poison, which has certain advantages as compared to taxanes in some laboratory experiments and shows clinical efficacy in breast cancer patients after failure of taxane and anthracycline treatment. Promising activity of neoadjuvant eribulin plus carboplatin combination was shown in previous TNBC studies [Kaklamani et al. Breast Cancer Res Treat, 2015]. This investigation aimed to directly compare the efficacy of neoadjuvant eribulin/carboplatin vs. paclitaxel/carboplatin doublets in TNBC patients.
Methods
61 TNBC patients (median age 45, range 31-76) were randomized to receive carboplatin AUC6 with either eribulin (1.1 mg/m2 on days 1 and 8, every three weeks) or paclitaxel (80 mg/m2 on days 1 and 8, every three weeks). Each patient was treated with four cycles of neoadjuvant therapy followed by surgery and four cycles of adjuvant FAC (5-fluorouracil 500 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2). After adjuvant chemotherapy, patients with breast-conserving surgery or with positive lymph nodes also received radiation treatment.
Results
The rates of clinical complete responses were similar in both cohorts (eribulin/carboplatin: 12/24 (50%); paclitaxel/carboplatin: 19/37 (51%)). Pathologic complete responses (pCR) were numerically less frequent in patients receiving eribulin [9/24 (38%) vs. 20/37 (54%)], although the difference was below statistical significance (p = 0.2). Five patients were carriers of deleterious BRCA1 alleles; pCRs were observed in 2/3 (67%) and 2/2 (100%) women in eribulin and paclitaxel arms, respectively. 56 patients had a follow-up above 12 months at the time of data analysis. 4/24 (17%) disease recurrences were documented in the eribulin arm, while only 1/32 (3%) TNBC relapse was noticed for paclitaxel (p = 0.15).
Conclusions
Eribulin plus carboplatin combination does not outperform, in terms of pathomorphological response to treatment, paclitaxel plus carboplatin doublet while given as a neoadjuvant treatment for triple-negative breast cancer.
Clinical trial identification
Legal entity responsible for the study
Petrov's National Medical Research Center for Oncology.
Funding
Russian Science Foundation [grant number 14-25-00111].
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract